> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Genentech sBLA OK’d for Tecentriq in Lung Cancer
- URL: https://www.fdaweb.com/genentech-sbla-okd-for-tecentriq-in-lung-cancer/
- Published: 2019-03-19T12:00:00.000Z
- Updated: 2026-09-15T01:13:54.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5143640

FDA has approved a Genentech sBLA for Tecentriq (atezolizumab) for combination use with carboplatin and etoposide (chemotherapy) for first-line treatment of adults with extensive-stage small cell lung cancer. Approval was based on data from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone (median overall survival 12.3 versus 10.3 months), according to the company. The Tecentriq-based combination also significantly improved progression-free survival compared to chemotherapy alone (5.2 versus 4.3 months). Safety appeared consistent with the therapy’s known safety profile, it says.